WARPTECHNEWS · LAB

Home AI Business Tech Archive

WARPTECH LAB NEWS

Warptech Lab News aggrega le notizie più rilevanti da oltre 700 fonti internazionali, con classificazione AI, TL;DR sintetici e timeline cluster su singole storie.

Navigazione

Home
Archivio
Editor's Brief
Cerca
Il tuo account
Newsletter tech/AI

Informazioni legali

Privacy Policy
Termini di servizio
Cookie Policy

© 2026 Sparktech S.R.L. — Tutti i diritti riservati. Sito gestito e manutenuto da Sparktech S.R.L.

Sede legale: Corso Libertà 55, 13100 Vercelli (VC), Italia · P.IVA / C.F. 02835910023 · Contatti: admin@warptechlab.com

Storia in 7 fonti

Does Revolution Medicines' pancreatic cancer drug have even greater potential?

Revolution Medicines' pancreatic cancer drug has not yet been approved — and already talk has shifted to how (and when) its use might be expanded.

Raccontata da

eu.usatoday.com

newscientist.com

hindustantimes.com

pharmaceutical-technology.com

scientificamerican.com

Confronto fonti

6 prospettive sulla stessa storia

AI · summaries

statnews.comStai leggendo1 mesi fa

Does Revolution Medicines' pancreatic cancer drug have even greater potential?

Revolution Medicines' pancreatic cancer drug has not yet been approved — and already talk has shifted to how (and when) its use might be expanded.

Timeline cronologica

lunedì 1 giugno 2026·eu.usatoday.com
Pancreatic cancer 'miracle' drug daraxonrasib doubles survival rate in new trial
The drug daraxonrasib nearly doubled the overall survival rates of pancreatic cancer patients. Here's how it works and who can get it.
lunedì 1 giugno 2026·newscientist.com
'Transformative' pancreatic cancer drug doubles survival time
People with advanced pancreatic cancer taking an experimental daily pill lived nearly twice as long as those receiving chemotherapy infusions

pharmaceutical-technology.com

1 mesi fa

ASCO26: RevMed’s daraxonrasib presents a turning point for pancreatic cancer - Pharmaceutical Technology

The field is ecstatic about the prospect of a targeted therapy meaningfully extending overall survival in pancreatic cancer.

Leggi questa versione → originale

hindustantimes.com1 mesi fa

Revolution Medicines' new cancer pill extends life: ‘Molecular glue’ works, study shows

Revolution Medicines' daraxonrasib extends median survival to 13.2 months in pancreatic cancer via a molecular glue approach targeting RAS mutations. For biotech strategists and tech leaders, the molecular glue approach demonstrates advances in structure-based drug design, opening new R&D paradigms in precision medicine.

Leggi questa versione → originale

startmag.it1 mesi fa

Tumore al pancreas, perché il farmaco di Revolution Medicines è rivoluzionario - Startmag

Daraxonrasib (Revolution Medicines) ha quasi raddoppiato la sopravvivenza mediana nel tumore pancreatico: 13,2 mesi vs 6,7 mesi, con riduzione mortalità del 60%. Primo inibitore RAS(ON) efficace su KRAS; sblocca classe considerata impossibile, estendibile a polmone e colon-retto oltre pancreas.

Leggi questa versione → originale

eu.usatoday.com1 mesi fa

Pancreatic cancer 'miracle' drug daraxonrasib doubles survival rate in new trial

The drug daraxonrasib nearly doubled the overall survival rates of pancreatic cancer patients. Here's how it works and who can get it.

Leggi questa versione → originale

scientificamerican.com1 mesi fa

Landmark pancreatic cancer treatment paves way for targeting other tricky tumors

Unprecedented results against a stubbornly hard-to-treat cancer are boosting optimism that other challenging tumors will be next

Leggi questa versione → originale

lunedì 1 giugno 2026·

hindustantimes.com

Revolution Medicines' new cancer pill extends life: ‘Molecular glue’ works, study shows

While the drug is not a cure, researchers say it could meaningfully improve both the length and quality of life for patients with advanced disease. | World News

lunedì 1 giugno 2026·

pharmaceutical-technology.com

ASCO26: RevMed’s daraxonrasib presents a turning point for pancreatic cancer - Pharmaceutical Technology

The field is ecstatic about the prospect of a targeted therapy meaningfully extending overall survival in pancreatic cancer.

martedì 2 giugno 2026·

hindustantimes.com

Scientifically Speaking: A pill takes on pancreatic cancer

For decades, the molecular switch that drives most pancreatic cancers was ‘undruggable’. No longer. A new drug has now nearly doubled how long patients live.

mercoledì 3 giugno 2026·

startmag.it

Tumore al pancreas, perché il farmaco di Revolution Medicines è rivoluzionario - Startmag

La presentazione dei risultati di daraxonrasib, una pillola sperimentale che nel tumore del pancreas metastatico ha quasi raddoppiato la

mercoledì 3 giugno 2026·

scientificamerican.com

Landmark pancreatic cancer treatment paves way for targeting other tricky tumors

Unprecedented results against a stubbornly hard-to-treat cancer are boosting optimism that other challenging tumors will be next

giovedì 4 giugno 2026·

statnews.com

Does Revolution Medicines' pancreatic cancer drug have even greater potential?

Revolution Medicines' pancreatic cancer drug has not yet been approved — and already talk has shifted to how (and when) its use might be expanded.

venerdì 5 giugno 2026·

statnews.com

Will Makary's FDA voucher program survive?

RevMed's cancer drug feels out of reach for some, SCOTUS preserves key generic drug pathway, and more biotech news